Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.370
-0.020 (-0.84%)
Feb 21, 2025, 4:00 PM EST - Market closed
Aerovate Therapeutics Employees
Aerovate Therapeutics had 51 employees as of December 31, 2023. The number of employees increased by 8 or 18.60% compared to the previous year.
Employees
51
Change (1Y)
8
Growth (1Y)
18.60%
Revenue / Employee
n/a
Profits / Employee
-$1,659,039
Market Cap
68.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51 | 8 | 18.60% |
Dec 31, 2022 | 43 | 27 | 168.75% |
Dec 31, 2021 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AVTE News
- 3 months ago - AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE - Business Wire
- 4 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - PRNewsWire
- 8 months ago - Aerovate Therapeutics to Explore Strategic Alternatives - GlobeNewsWire
- 8 months ago - Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC - GlobeNewsWire
- 8 months ago - Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm - GlobeNewsWire
- 8 months ago - Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire
- 9 months ago - Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market - Seeking Alpha
- 9 months ago - Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference - GlobeNewsWire